Pelthos Therapeutics reported a gross margin of 80.07% and a net margin of -182.92% for the quarter ended Jun 2026. These financial ratios cover 12 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2022 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||
| Gross Margin | 68.73% | 81.61% | 84.66% | 80.07% | ||||||||
| EBT Margin | -225.53% | -314.34% | -229.90% | -182.92% | ||||||||
| EBIT Margin | -207.43% | -131.99% | -120.01% | -114.72% | ||||||||
| EBITDA Margin | -207.43% | -131.99% | -120.01% | -114.72% | ||||||||
| Operating Margin | -207.43% | -131.99% | -120.01% | -114.72% | ||||||||
| Net Margin | -219.25% | -238.22% | -229.90% | -182.92% | ||||||||
| FCF Margin | -206.04% | -68.75% | -122.13% | -79.17% | ||||||||
| Efficiency | ||||||||||||
| Inventory AverageInventory Avg. | 23.84M | 23.50M | 22.45M | |||||||||
| Assets AverageAssets Avg. | 2.06M | 3.32M | 2.37M | 1.75M | 1.14M | 0.87M | 63.63M | 128.41M | 137.89M | 141.37M | ||
| Invested CapitalInvested Cap. | -3.60M | -5.69M | -0.05M | -1.30M | -0.53M | -4.06M | -6.36M | 38.88M | 45.62M | 25.09M | ||
| Asset Utilization RatioAsset Util. | 0.13 | 0.20 | 0.38 | |||||||||
| Leverage & Solvency | ||||||||||||
| Interest Coverage RatioInterest Cover | -52.54 | -16.89 | -13.69 | -14.82 | -11.41 | -9.13 | -5.56 | -6.41 | ||||
| Debt Ratio | 1.90 | 7.78 | 0.05 | 0.06 | 1.60 | 0.14 | 0.16 | 0.18 | 0.19 | |||
| Times Interest Earned | -52.54 | -16.89 | -13.69 | -14.82 | -11.41 | -9.13 | -5.56 | -6.41 | ||||
| Valuation | ||||||||||||
| Price to EarningsP/E | -4.80 | -4.34 | -2.44 | -2.03 | -4.46 | 2.42 | -5.33 | -2.69 | -2.82 | -2.17 | ||
| Price to SalesP/S | 11.69 | 6.41 | 6.49 | 3.96 | ||||||||
| Price to BookP/B | 10.88 | -41.77 | -2.89 | -1.44 | -2.09 | -1.31 | 1.49 | 1.50 | 3.67 | -70.01 | ||
| Enterprise Value | 8.52M | 5.28M | 3.62M | 3.40M | 8.65M | 8.42M | 72.24M | 40.27M | 38.58M | 80.53M | ||
| EV to EBIT | -4.41 | -2.99 | -1.77 | -1.86 | -4.72 | -2.61 | -4.70 | -3.36 | -2.95 | -2.65 | ||
| EV to EBITDA | -4.41 | -2.99 | -1.77 | -1.86 | -4.72 | -2.61 | -4.70 | -3.36 | -2.95 | -2.65 | ||
| Market Capitalization | 12.29M | 7.69M | 4.13M | 3.91M | 8.78M | 8.48M | 86.54M | 58.30M | 70.80M | 105.09M | ||
| Price to FCFP/FCF | -6.17 | -2.60 | -23.25 | -5.84 | -13.89 | -18.98 | -5.67 | -9.32 | -5.32 | -5.01 | ||
| EV to FCF | -4.28 | -1.79 | -20.36 | -5.07 | -13.69 | -18.85 | -4.73 | -6.44 | -2.90 | -3.84 | ||
| EV to CFO | -4.28 | -1.79 | -20.36 | -5.07 | -13.69 | -18.85 | -4.73 | -6.44 | -2.94 | -3.87 | ||
| Return Ratios | ||||||||||||
| Return on Sales [ROS]ROS | -207.43% | -131.99% | -120.01% | -114.72% | ||||||||
| Return on Capital Employed [ROCE]ROCE | 941.14% | -1,668.73% | 805.08% | 325.14% | 188.33% | 138.57% | -57.26% | -31.66% | -38.70% | -64.77% | ||
| Return on Invested Capital [ROIC]ROIC | -93.04% | -187.97% | ||||||||||
| Return on Assets [ROA]ROA | -434.92% | -295.24% | -424.50% | -453.42% | -645.62% | -1,042.43% | -37.06% | -33.73% | -48.17% | -78.85% |